Advantages:

Vitrectomy for diabetic macula edema (DME) is and was used as a second line treatment. Published studies about this therapy option report mainly about small numbers of patients and show heterogenous results. In these times, when ranibizumab starts to dominate the therapy of DME, we want to present the functional results of vitrectomy for DME in a larger number of treated eyes.

Methods:

Retrospective analysis of the functional outcome of 331 eyes, treated between 2001 and 2006 with vitrectomy with ICG-assisted ILM-peeling for diabetic macular edema.

Effectiveness / Safety:

The mean follow-up was 1.8 ± 1.9 years. During the first year after surgery, eyes with a VA of >0.3 before the surgery, showed a loss of vision.